Channel 3 - The Rare Disease Channel

About Channel 3 - The Rare Disease Channel

The Podcast Channel of Channel ONE (Dailymotion und YouTube)

Publisher

Channel 3

Category

health & fitness

Language

de

Explicit

No

First episode

31 May 2025

Latest episode

10 Jun 2025

Latest episodes

6 episodes in the feed.

1. 

   10 Jun 2025

   Die erste Guideline zum H63D-Syndrom ist verfügbar!

   This episode discusses the first guideline for H63D syndrome, a rare multisystem disorder, emphasizing diagnostic challenges and the need for individualized, multidisciplinary treatment.

2. 

   8 Jun 2025

   Wie man das H63D-Syndrom mit dem “Eisenstatus” beim Hausarzt ertappen kann!

   This episode discusses how to identify H63D syndrome through iron status testing, advising immediate genetic testing when transferrin decreases, transferrin saturation increases, and ferritin decreases.

3. 

   8 Jun 2025

   Über das lebensgefährliche Oshtoran-Syndrom und Ärzte, die Patienten zu medizinischen Waisen machen

   This episode discusses the life-threatening Oshtoran Syndrome and how some doctors can leave patients feeling like medical orphans.

4. 

   7 Jun 2025

   Wie das H63D-Syndrom und komplett unfähige Ärzte einen jungen Mann zum Behinderten machten

   Michael shares his harrowing experience with H63D syndrome and the medical system's failures, highlighting the devastating consequences of overlooked rare diseases.

5. 

   31 May 2025

   Erkennen von H63D-Syndrom und Oshtoran-Syndrom: Transferrin ↓ Transferrinsättigung ↑ Ferritin ↓

   This episode discusses the critical importance of recognizing specific iron status markers like low Transferrin, high Transferrin saturation, and low Ferritin to identify systemic iron dysregulation and prevent adverse health outcomes.

6. 

   31 May 2025

   PubMed ist Wissenschaftsimperialismus

   Professor Georg Schuster discusses PubMed's alleged scientific imperialism during a lecture at the Jewish University of Colorado, sparking debate on research integrity; this is an interview.